News

With the Covid-19 pandemic affecting every industry in the world, including the microfinance sector, Symbiotics and CGAP have partnered to publish a series of briefs that explore how Covid-19 has affected the microfinance sector based on Symbiotics’ data and our analysts’ expertise. Four briefs that

This latest update confirms that global microfinance recovery continues, especially in Africa, but pandemic’s longterm impact remains uncertain.

Read the latest snapshot : Snapshot: MFIs During the Crisis – July 2021

About this snapshot
This snapshot is part of a series published by CGAP an

This latest update confirms that the microfinance sector remains resilient and on its way to a cautious and gradual recovery, but the pace depends on type of institution, region, and capital buffers.

Read the latest snapshot with a spotlight on Latin America: Snapshot: MFIs During the Crisis – Ap

Shefali’s travel notes, Investment Analyst in Singapore
When I arrived in India a couple weeks ago, after many months confined in Singapore, the most bizarre thing of all that struck me was how normal things appeared. At least superficially. The usual hustle and bustle on the streets has resumed

This update confirms that MFIs remain resilient. A year into the COVID-19 pandemic, liquidity concerns in the microfinance sector have not materialized as anticipated. Where loan payments moratoria ended, repayments rates have been encouraging. Disbursements are also picking up again, closer to what

CGAP and Symbiotics launched a partnership to track and analyze the performance of hundreds of microfinance institutions (MFIs) across the world over the next six months, in an ongoing effort to shed light on how the COVID-19 pandemic is impacting the microfinance sector.

The COVID-19 pandemic ha

Geneva, March 18, 2020

Dear Clients and Partners,

We would like to update you on Symbiotics’ response to the pandemic situation and public health policies being put in place in our various markets and locations.

Our priority is to reduce the risk of infection of our clients, partners and